Physician profile
Michael Brown
NPI 1861488637
$17,197.02
in general payments reported to CMS, 2019-2025
32 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,529 · 2020: $192 · 2021: $619 · 2022: $1,091 · 2023: $1,568 · 2024: $2,436 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,765.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,620.68 | 2019-2025 | |
| Abbvie INC. | $2,401.50 | 2020-2025 | Linzess, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $929.89 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $590.27 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $509.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $443.15 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $357.57 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $326.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $312.28 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $311.63 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $294.55 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $288.97 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $276.15 | 2024-2025 | Sucraid, Sucraid |
| Celgene Corporation | $251.53 | 2021-2024 | Zeposia |
| Medtronic, INC. | $191.89 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $145.77 | 2022-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $121.77 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.50 | 2021 | |
| Ferring Pharmaceuticals INC. | $106.06 | 2023-2024 | Rebyota |
| Cook Medical LLC | $87.81 | 2021 | |
| Echosens North America, INC. | $85.49 | 2021-2023 | Fibroscan |
| Novo Nordisk INC | $55.28 | 2024-2025 | Wegovy |
| Boston Scientific Corporation | $53.63 | 2019-2023 | Resolution 360 Clip |
| Braintree Laboratories, INC. | $52.99 | 2021-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $47.55 | 2020-2021 | |
| Redhill Biopharma INC. | $45.34 | 2021 | |
| Endogastric Solutions, INC | $41.44 | 2022-2024 | Esophyx |
| Intercept Pharmaceuticals, INC. | $39.79 | 2023-2024 | Ocaliva |
| Evoke Pharma, INC. | $30.98 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $29.82 | 2024 | Iqirvo |
| Daiichi Sankyo INC. | $19.69 | 2025 | Injectafer |
| Allergan, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.